Prothena Biosciences (PRTA): Forward Price-to-Revenue Multiple
Prothena Corporation focuses on developing antibodies to clear organs of toxic proteins associated with Parkinson's disease. The issuer's forward P/S reflects market expectations, where the value 8.00 represents the most recent figure. The company's high scientific standing in neurodegeneration therapy is supported by the consistent performance of its research laboratories and the expansion of its cloud IT infrastructure for genomic data analysis.
Comprehensive metric breakdowns and analytics for Prothena Biosciences (PRTA)
- current price and projected stock value:
- stock exchange capitalization data:
- business book valuation details:
- debt and solvency information:
Debt to Equity Prothena Corporation|PRTA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Prothena Corporation|PRTA - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Prothena Biosciences|PRTA - Long-Term Debt|Company Short-Term Debt Prothena|Quick Ratio prothena.com
- financial results and valuation multiples details:
PRTA - Net Profit|Future Profit Prothena Corporation|PRTA - Market Price to Net Income Ratio|Forward P/E Multiple Prothena Corporation plc|PRTA - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prothena Biosciences|PRTA - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Prothena|PRTA - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months prothena.com|PRTA - Earnings per share trend in current year|Net earnings per share growth forecast for next year Prothena Corporation
- sales and revenue data:
Fundamental valuation:PRTA (Prothena)
The forward P/S ratio relates current market capitalization to expected sales volume, allowing investors to assess the degree to which an asset is overbought relative to projected cash flows. By analyzing the trend of the forward P/S metric, one can identify trend reversals in the valuation of Prothena Corporation (PRTA) and its innovative potential to develop targeted antibodies for the therapy of neurodegenerative diseases in partnership with global pharma behemoths.
Competitor analysis
Forward P/S Multiple BIIB (Biogen)|Forward P/S Multiple Neurocrine NBIX|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Corp)|ACAD: Forward P/S Multiple|Forward Price-to-Revenue Multiple xenon-pharma.com|Price-to-Projected Revenue Ratio Viking Therapeutics, Inc.|Market Cap to Future Revenue Ratio Supernus Pharmaceuticals, Inc. SUPN|Price-to-Projected Revenue Ratio Catalyst Pharmaceuticals Inc (CPRX)|DNLI (Denali Corp) - Forward Price to Sales|Price-to-Projected Revenue Ratio Harmony Biosciences HRMY|BHVN (biohavenpharma.com) - Future Price to Revenue|AMLX - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Trevi Therapeutics Inc|Praxis Medicines (PRAX) - Price-to-Projected Revenue Ratio|Anavex Life Sciences Corp - Forward Price to Sales|CBLL (CeriBell, Inc.) - Forward P/S Multiple|Forward P/S Multiple Alector Therapeutics|Forward Price-to-Revenue Multiple ANNX (Annexon)|Price to Expected Revenue Ratio OMER|Forward P/S Multiple NGNE (Neurogene Corp)|Market Cap to Expected Sales Ratio AC Immune Inc (ACIU)|VYGR - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio neumoratx.com|Scilex (SCLX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TVGN|Price-to-Projected Revenue Ratio Alpha Cognition Inc|Cognition Therapeutics Inc. - Future Price to Revenue|Price-to-Projected Revenue Ratio Inhibikase Therapeutics (IKT)|SAVA (cassavasciences.com) - Forward Price to Sales|Assertio - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio COYA (Coya Therapeutics Inc)|VistaGen Therapeutics Inc - Forward P/S Multiple|OVID - Forward P/S Multiple|Acumen Pharmaceuticals (ABOS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue CRVO|ATHE (Alterity Therapeutics Ltd.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Clene Nanomedicine CLNN|Forward Price-to-Revenue Multiple PEPG (PepGen Inc.)|Forward P/S Multiple Jupiter Neurosciences, Inc. (JUNS)|Price-to-Projected Revenue Ratio Relmada Therapeutics RLMD|Forward Price to Sales ANVS|GRCE - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Firefly Neuroscience, Inc.|anewmeds.com (KLTO) - Price-to-Projected Revenue Ratio|Future Price to Revenue NRSN (NeuroSense Therapeutics Ltd.)|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals|MTVA: Forward Price to Sales|Price-to-Projected Revenue Ratio NeurAxis (NRXS)|HSDT - Market Cap to Future Revenue Ratio|Passage Bio - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio NEUP (Neuphoria Therapeutics, Inc.)|Minerva Neurosciences - Forward P/S Multiple|Forward Price to Sales ATHA (athira.com)|ADXN: Forward P/S Multiple|Market Cap to Future Revenue Ratio Alzamend Neuro (ALZN)|Price-to-Projected Revenue Ratio Cyclerion Therapeutics Inc.|Market Cap to Projected Revenue PTIX (Protagenic)|Forward P/S Multiple KTTA|Forward P/S Multiple cortigent.com (CRGT)|Avenue Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales BCLI|Cara Therapeutics, Inc - Forward P/S Multiple|Chromocell (CHRO) - Forward Price-to-Revenue Multiple|eliemtx.com (ELYM) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|Price-to-Projected Revenue Ratio Longboard Pharmaceuticals, Inc.|MRNS: Forward Price to Sales|Price-to-Projected Revenue Ratio NKGen (NKGN)|NRBO: Future Price to Revenue|Price-to-Projected Revenue Ratio Sage Therapeutics, Inc. SAGE|synaptogen.com (SNPX) - Market Cap to Future Revenue Ratio|TRVN - Price-to-Projected Revenue Ratio|Forward Price to Sales VIGL (Vigil Neuroscience)|WENA: Forward P/S Multiple|Cerevel Corp (CERE) - Forward P/S Multiple
